MARKET

DVAX

DVAX

Dynavax Techs
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.34
-0.30
-3.47%
Opening 10:33 03/03 EST
OPEN
8.60
PREV CLOSE
8.64
HIGH
8.77
LOW
8.32
VOLUME
660.95K
TURNOVER
--
52 WEEK HIGH
12.44
52 WEEK LOW
1.800
MARKET CAP
944.56M
P/E (TTM)
-10.7170
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Dynavax to Present at the H.C. Wainwright Virtual 2021 Global Life Sciences Conference
Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer, Chief Executive Officer, will present at the H.C. Wainwright Virtual 2021 Global Life Scienc...
PR Newswire · 1d ago
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that in connection with the commencement of Ms. MacDonald's employment with the Company as Senior Vice President and Chief Financial Officer on March 1, 2021, the Company granted her a non-stat...
PR Newswire · 1d ago
Global Oligonucleotide-based Therapies Market 2020 Industry Analysis, Key Drivers, Business Strategy, Opportunities and Forecast to 2025
Mar 01, 2021 (CDN Newswire via Comtex) -- MarketsandResearch.biz has announced the addition of a new report entitled Global Oligonucleotide-based Therapies...
CDN Newswire · 2d ago
Cancer Vaccines Market 2021 By Usage, Functionality, Service, Application, Solution, Type, Industry Analysis, Size, Share, Latest-Technology, Trends and Forecast 2028
The Express Wire · 3d ago
Are These The Top Biotech Stocks To Buy In March? 4 Names To Consider
StockMarket.com · 4d ago
Dynavax surges on prospects for COVID–19 vaccine adjuvant
Dynavax Technologies ([[DVAX]] +8.6%) is on the rise today after the company estimated its CpG 1018, an adjuvant for COVID-19 vaccine candidates, to contribute millions of dollars in revenue in
Seekingalpha · 4d ago
Endo's (ENDP) Earnings & Revenues Surpass Estimates in Q4
Zacks.com · 4d ago
Xtant Medical, Sensus Healthcare leads healthcare gainers; Tricida, Recro Pharma among major losers
Gainers: Xtant Medical (XTNT) +54%, Sensus Healthcare (SRTS) +34%, Rubius Therapeutics (RUBY) +23%, Select Medical (SEM) +18%, Dynavax Technologies (DVAX) +18%.Losers: Tricida (TCDA) -32%, Recro Pharma (REPH) -27%, Zynex (ZYXI) -17%, NLS Pharmaceutics (NLS...
Seekingalpha · 4d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DVAX. Analyze the recent business situations of Dynavax Techs through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average DVAX stock price target is 18.00 with a high estimate of 20.00 and a low estimate of 16.00.
EPS
Institutional Holdings
Institutions: 255
Institutional Holdings: 101.84M
% Owned: 89.92%
Shares Outstanding: 113.26M
TypeInstitutionsShares
Increased
53
7.25M
New
42
-2.38M
Decreased
43
8.83M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.75%
Pharmaceuticals & Medical Research
-1.75%
Key Executives
Chairman/Independent Director
Andrew Hack
President/Chief Operating Officer
David Novack
Chief Executive Officer/Director
Ryan Spencer
Chief Financial Officer/Senior Vice President
Kelly MacDonald
Senior Vice President/Chief Compliance Officer/General Counsel/Secretary
Steven Gersten
Senior Vice President/Director of Human Resources
Jeff Coon
Senior Vice President
Robert Janssen
Senior Vice President
Dong Yu
Chief Accounting Officer
Justin Burgess
Director
Julie Eastland
Director
Brent MacGregor
Director
Peter Paradiso
Independent Director
Francis Cano
Independent Director
Daniel Kisner
Independent Director
Arnold Oronsky
Independent Director
Peggy Phillips
Independent Director
Natale Ricciardi
  • Dividends
  • Splits
  • Insider Activity
No Data
About DVAX
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Its products include HEPLISAV-B, AZD1419, DV281, DV230F and DV1001. HEPLISAV-B is an investigational adult hepatitis B vaccine. AZD1419 is being developed for the treatment of asthma. DV281 is an investigational TLR9 agonist designed specifically for focused delivery to primary lung tumors and lung metastases. DV230F is indicated for the treatment of Liver Tumors. DV1001 targets TLR 7 and 8 agonist for multiple malignancies. DV230F and DV1001 are in pre-clinical stage of development.

Webull offers kinds of Dynavax Technologies Corporation stock information, including NASDAQ:DVAX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DVAX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DVAX stock methods without spending real money on the virtual paper trading platform.